Literature DB >> 19339902

CDKN2A and MC1R analysis in amelanotic and pigmented melanoma.

Paola Ghiorzo1, Lorenza Pastorino, Maria A Pizzichetta, Riccardo Bono, Paola Queirolo, Renato Talamini, Giorgio Annessi, William Bruno, Sabina Nasti, Sara Gargiulo, Linda Battistuzzi, Maria C Sini, Giuseppe Palmieri, Giovanna Bianchi Scarrà.   

Abstract

Amelanotic melanoma (AM) is a rare subtype of melanoma with little or no clinically visible pigment; it is more difficult to diagnose than pigmented melanoma (PM), and has a worse prognosis. In the attempt to find a genetic explanation for the distinction between AM and PM, we conducted a case-case study, matching AM and PM patients, and testing them for germline mutations in high- (p16INK4A, p14ARF, CDK4) and low-penetrance (MC1R) melanoma susceptibility genes. Similar CDKN2A mutations were found in both sets of melanomas. A p14ARF splice germline mutation was detected for the first time in an Italian family with AM. This rare mutation, which has been described only once previously, may be involved in predisposition to the amelanotic phenotype in combination with germline MC1R variants and coordinate somatic expression of pigmentation genes and their regulators.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19339902     DOI: 10.1097/CMR.0b013e32832a1e18

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  5 in total

Review 1.  Epidemiological and genetic factors underlying melanoma development in Italy.

Authors:  Giuseppe Palmieri; Maria Colombino; Milena Casula; Mario Budroni; Antonella Manca; Maria Cristina Sini; Amelia Lissia; Ignazio Stanganelli; Paolo A Ascierto; Antonio Cossu
Journal:  Melanoma Manag       Date:  2015-05-18

2.  Association of Incident Amelanotic Melanoma With Phenotypic Characteristics, MC1R Status, and Prior Amelanotic Melanoma.

Authors:  Steven Vernali; Weston T Waxweiler; Patrick M Dillon; Peter A Kanetsky; Irene Orlow; Li Luo; Klaus J Busam; Anne Kricker; Bruce K Armstrong; Hoda Anton-Culver; Stephen B Gruber; Richard P Gallagher; Roberto Zanetti; Stefano Rosso; Lidia Sacchetto; Terence Dwyer; Anne E Cust; David W Ollila; Colin B Begg; Marianne Berwick; Nancy E Thomas
Journal:  JAMA Dermatol       Date:  2017-10-01       Impact factor: 10.282

3.  Inherited variants in the MC1R gene and survival from cutaneous melanoma: a BioGenoMEL study.

Authors:  John R Davies; Juliette Randerson-Moor; Kairen Kukalizch; Mark Harland; Rajiv Kumar; Srinivasan Madhusudan; Eduardo Nagore; Johan Hansson; Veronica Höiom; Paola Ghiorzo; Nelleke A Gruis; Peter A Kanetsky; Judith Wendt; Dace Pjanova; Susana Puig; Philippe Saiag; Dirk Schadendorf; Nadem Soufir; Ichiro Okamoto; Paul Affleck; Zaida García-Casado; Zighereda Ogbah; Aija Ozola; Paola Queirolo; Antje Sucker; Jennifer H Barrett; Remco van Doorn; D Timothy Bishop; Julia Newton-Bishop
Journal:  Pigment Cell Melanoma Res       Date:  2012-03-16       Impact factor: 4.693

4.  Melanocortin-1 receptor, skin cancer and phenotypic characteristics (M-SKIP) project: study design and methods for pooling results of genetic epidemiological studies.

Authors:  Sara Raimondi; Sara Gandini; Maria Concetta Fargnoli; Vincenzo Bagnardi; Patrick Maisonneuve; Claudia Specchia; Rajiv Kumar; Eduardo Nagore; Jiali Han; Johan Hansson; Peter A Kanetsky; Paola Ghiorzo; Nelleke A Gruis; Terry Dwyer; Leigh Blizzard; Ricardo Fernandez-de-Misa; Wojciech Branicki; Tadeusz Debniak; Niels Morling; Maria Teresa Landi; Giuseppe Palmieri; Gloria Ribas; Alexander Stratigos; Lynn Cornelius; Tomonori Motokawa; Sumiko Anno; Per Helsing; Terence H Wong; Philippe Autier; José C García-Borrón; Julian Little; Julia Newton-Bishop; Francesco Sera; Fan Liu; Manfred Kayser; Tamar Nijsten
Journal:  BMC Med Res Methodol       Date:  2012-08-03       Impact factor: 4.615

5.  Pigmentary Markers in Danes--Associations with Quantitative Skin Colour, Nevi Count, Familial Atypical Multiple-Mole, and Melanoma Syndrome.

Authors:  Peter Johansen; Jeppe Dyrberg Andersen; Linnea Nørgård Madsen; Henrik Ullum; Martin Glud; Claus Børsting; Robert Gniadecki; Niels Morling
Journal:  PLoS One       Date:  2016-03-03       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.